U.S. Markets closed

PhaseBio Pharmaceuticals, Inc. (PHAS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.7800+0.0900 (+2.44%)
At close: 1:00PM EST
Sign in to post a message.
  • U
    Unknown
    GOOD NEWS FOR US

    PhaseBio ( $PHAS ) has decided to terminate their clinical trial for Pemziviptadil / PB1046 - their VIP analogue - in the treatment of severe COVID patients.
  • c
    chingis
    Fair play to the management for announcing the termination of the covid trial.
    Unfortunately, small cap Biotechs have a reputation for companies being run basically for the benefit of the management, with dilution and pump and dump schemes a common event.
    I know that there is a substantial amount of optimism over at Relief Therapeutics that they will shortly obtain an EUA for Covid treatment . There were many who believed that this would also indicate that PB1046 would have been effective in treating Covid. It would’ve been very easy for the management to have engineered a delay to the announcement of the termination of the Trial and to encourage the share price to run up .
    ultimately for the benefit of management and the detriment of shareholders.
    That this did not happen reflects well upon the integrity of the management and although I originally came to this company as a possible covid play, I always viewed that as essentially a free option based upon the other products in the pipeline.
  • J
    Jeff
    Happy Thanksgiving everyone
  • M
    Manny
    $RLFTF conversation
    I usually buy with stocks that drop with no news. But this is way too suspicious. I’m holding. I’ve heard some rumors of the $PHAS trial stopping being the reason. It’s a VIP drug that decided to drop their trial. This to me is no news for $RLFTF but that’s what I’m hearing.
  • P
    Phillip
    Why the sudden mid-day pop? News pending?
  • t
    tcmoiba
    Some VIP info. Good that the current Clinical Trial has many indications covered. Results by Dec2020. Yes sure this is a Covid play but Much more. 90% institutions/insiders, super low float...GLTA...

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852716/
    Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for bronchodilatory, immunomodulatory and
    Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for bronchodilatory, immunomodulatory and
    www.ncbi.nlm.nih.gov
  • Y
    Yahoo Finance Insights
    PhaseBio Pharmaceuticals is down 9.36% to 3.10
  • c
    chingis
    Does anyone know if there has been an interim review of the Vanguard trial, I understand that this is expected to conclude late fourth quarter of 20 20. However, I recently saw an interview with one of the participating hospitals saying that they were no longer enrolling patients , does this mean that they have reached full enrolment?
  • Y
    Yahoo Finance Insights
    PhaseBio Pharmaceuticals is up 8.76% to 2.98
  • D
    DONALD
    $18. Soon.
  • S
    Steve
    will fall before rise again
    Bearish
  • A
    ARGELIOM
    @BigGator This is a follow up to my previous post to you regarding Dr. Yo's interview with Dr. Javitt. You can find Dr. Javitt's explanation to the difference between PHAS and RLFTF therapeutics between minutes 22 to 24. The rationale provide by Dr. Javitt's why they are differ is due to different MOAs. Specifically, PHAS is VACP2 selective (blood vessel dialation) why RLFTF is VACP1 (Lung) selective. I emailed PhaseBio regarding the interview but never received a response.
  • S
    Steve
    Did you know that blood circulates in the lungs? 😆😄
    Bullish
  • P
    Phillip
    Does anyone know the earnings date?
  • J
    Jon
    Wondering why RLFTF is doing so much better than this company if they are both working with the same molecule? Can anyone shed some light on this?

    Thanks

    Jon
  • S
    Steve
    Someone playing with 5 million here😁
    Bullish
  • B
    BigGator
    Investments of this nature are necessarily high risk - you have your FDA/clinical trials issues, you have the size of the company and capitalization, you're on an exchange where the fair disclosure rule doesn't apply in general; so when I post to any message boards I always note one should know his or her risk tolerance. With those qualifications in mind and as you can see I'm no pumper, I am quite bullish here. Like so many companies big and small, phasebio rushed to toss a candidate and covid-19. The information from relief therapeutics on their aviptadil candidate, if genuine, offers some weight in the direction of a favorable outcome for the phasebio candidate but certainly not why I chose to invest. the blood thinner reversal candidate looks like all but a sure thing for approval. so given that the real risks here pertain to how the company is structured and finance going forward and in particular what the insider stockholders ultimately arrange wants the candidate is approved. minority shareholders sometimes receive less value as Insiders structure compensation from a buyout company etc that allows them to benefit outside of the stock price.
    stick with the Gators keep a little money in this game it helps remind us to check on the stock this one is very interesting
    Bullish
  • D
    Dan
    10% after hours on a Friday. No news that I see. Any thoughts?
  • B
    Bob
    The presentation at HC Wainwright just concluded. It was very informative and the slides were extremely helpful and easy to understand. Safe to say, if you wanted to pick up some shares at this price range you will have a month or two to do so. News is expected for the ongoing trials, especially for the COVID19 application by the end of the year. Very pleased with the presentation.
  • F
    Frank
    It is a bit ironic, but the main reason why I invested into this stocks are data generated by another company on the V.I.P. - see here. These data are really good and this indicates to me that VIP really works and it works well, these data are really impressive:

    https://relieftherapeutics.com/relief-therapeutics-and-neurorx-note-submission-of-clinical-results-from-21-patient-study-for-publication

    https://dx.doi.org/10.2139/ssrn.3665228